Observations placeholder
Sitagliptin Phosphate
Identifier
020034
Type of Spiritual Experience
Number of hallucinations: 7
Background
A description of the experience
Sitagliptin (INN , previously identified as MK-0431 and marketed as the phosphate salt under the trade name Januvia) is an oral antihyperglycemic (antidiabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. This enzyme-inhibiting drug is used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a thiazolidinedione) for treatment of diabetes mellitus type 2.
The benefit of this medicine is its fewer side effects (e.g., less hypoglycemia, less weight gain) in the control of blood glucose values. While safety is its advantage, efficacy is often challenged as it is often recommended to be combined with other agents such as metformin.
On Dec, 12, 2016 1,636 people reported to have side effects when taking Sitagliptin Phosphate. Among them, 7 people (0.43%) have Hallucination
On Feb, 8, 2016: 864 people reported to have side effects when taking Sitagliptin phosphate. Among them, 20 people (2.31%) have Death.
Time on Sitagliptin phosphate when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 0.00% | 37.50% | 0.00% | 62.50% | 0.00% | 0.00% | 0.00% |
Gender of people who have Death when taking Sitagliptin phosphate :
| Female | Male | |
| Death | 41.18% | 58.82% |